Moderna to Expand its Massachusetts Manufacturing Technology Center
Moderna will double the space at its Moderna Technology Center in Norwood, MA, to transform it from a production and lab space into an industrial technology center.
Moderna announced on May 4, 2021 that it is doubling the space of its Moderna Technology Center in Norwood, MA, to transform it from a production and lab space into an industrial technology center.
The expansion will include increasing the facility’s production and lab space from 30,000 ft2 to 650,000 ft2 through renovations and the acquisition of an additional 240,000-ft2 space located on the same campus, Moderna said in a company press release. The expansion will also include a 50% increase in production of Moderna’s COVID-19 vaccine and an increase in the company’s technical development capacity and preclinical production capabilities.
“Our manufacturing facility has been core to our long-term strategy and has enabled us to provide the scale and flexibility to support the development of our mRNA [messenger RNA] medicines and vaccines, including our COVID-19 vaccine,” said Stéphane Bancel, CEO of Moderna, in the press release. “We believe that this investment and expansion at our technology center will allow us to continue to optimize our mRNA products as we explore new pharmaceutical delivery forms, such as prefilled syringes and lyophilized products. As we grow, we are committed to minimizing our environmental footprint.”
Source: Moderna
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
